Chromosomal imbalances in nasopharyngeal carcinoma: a meta-analysis of comparative genomic hybridization results
2006; 4: 4
Hydralazine target: From blood vessels to the epigenome
2006; 4: 10
Establishment and characterization of multicellular spheroids from a human glioma cell line; Implications for tumor therapy
2006; 4: 12
Tumor-associated endothelial cells display GSTP1 and RARβ2 promoter methylation in human prostate cancer
2006; 4: 13
The use of microarray technologies in clinical oncology
2006; 4: 8
Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance
2006; 4: 11
Cytokines, GM-CSF and IFNγ administered by priming and post-chemotherapy cycling in recurrent ovarian cancer patients receiving carboplatin
2006; 4: 16
An alternative flow cytometry strategy for peripheral blood dendritic cell enumeration in the setting of repetitive GM-CSF dosing
2006; 4: 18
Rewarding patient-directed research: Excellence in Translational Medicine Award
2006; 4: 19
Laser-assisted blastocyst dissection and subsequent cultivation of embryonic stem cells in a serum/cell free culture system: applications and preliminary results in a murine model
2006; 4: 20
Bacteria and cancer: cause, coincidence or cure? A review
2006; 4: 14
Perioperative intraperitoneal chemotherapy for peritoneal surface malignancy
2006; 4: 17
Induction of antitumor immunity through xenoplacental immunization
2006; 4: 22
Clonal analysis of palmar fibromatosis: a study whether palmar fibromatosis is a real tumor
2006; 4: 21
Innate immune functions of microglia isolated from human glioma patients
2006; 4: 15
Combined IL-21 and Low-Dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model
2006; 4: 24
Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy
2006; 4: 25
The expression of p63 is associated with the differential stage in nasopharyngeal carcinoma and EBV infection
2006; 4: 23
Papillary microcarcinomas of the thyroid gland and immunohistochemical analysis of expression of p53 protein in papillary microcarcinomas
2006; 4: 28
Monocyte/macrophage and T-cell infiltrates in peritoneum of patients with ovarian cancer or benign pelvic disease
2006; 4: 30
"Ejaculatory disorders and α1-adrenoceptor antagonists therapy: clinical and experimental researches"
2006; 4: 31
Gene expression in acute Stanford type A dissection: a comparative microarray study
2006; 4: 29
Microarray evidence of glutaminyl cyclase gene expression in melanoma: implications for tumor antigen specific immunotherapy
2006; 4: 27
Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsets
2006; 4: 26
Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients
2006; 4: 36
Azithromycin in Chronic Fatigue Syndrome (CFS), an analysis of clinical data
2006; 4: 34
Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine
2006; 4: 32
HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer
2006; 4: 38
Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma
2006; 4: 35
Affordable flow cytometry for enumeration of absolute CD4+ T-lymphocytes to identify subtype C HIV-1 infected adults requiring antiretroviral therapy (ART) and monitoring response to ART in a resource-limited setting
2006; 4: 33
Proteomic definition of a desmoglein linear determinant common to Pemphigus vulgaris and Pemphigus foliaceous
2006; 4: 37
Functional expression of a single-chain antibody to ErbB-2 in plants and cell-free systems
2006; 4: 39
Comparison of proteomic profiles of serum, plasma, and modified media supplements used for cell culture and expansion
2006; 4: 40
Immunological consequences of using three different clinical/laboratory techniques of emulsifying peptide-based vaccines in incomplete Freund's adjuvant
2006; 4: 42
Preliminary data on Pemphigus vulgaris treatment by a proteomics-defined peptide: a case report
2006; 4: 43
Recent advances in the bcr-abl negative chronic myeloproliferative diseases
2006; 4: 41
Distribution of killer cell immunoglobulin-like receptors genes in the Italian Caucasian population
2006; 4: 44
A novel assay for analysis of the regulation of the function of human osteoclasts
2006; 4: 45
Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment
2006; 4: 48
Characterization of highly frequent epitope-specific CD45RA+/CCR7+/- T lymphocyte responses against p53-binding domains of the human polyomavirus BK large tumor antigen in HLA-A*0201+ BKV-seropositive donors
2006; 4: 47
Antimicrobial effects of liquid anesthetic isoflurane on Candida albicans
2006; 4: 46
In vivo migration of labeled autologous natural killer cells to liver metastases in patients with colon carcinoma
2006; 4: 49
A gene expression signature associated with survival in metastatic melanoma
2006; 4: 50
In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer
2006; 4: 52
Consequences of infertility in developing countries: results of a questionnaire and interview survey in the South of Vietnam
2006; 4: 54
Differential expression profiling between the relative normal and dystrophic muscle tissues from the same LGMD patient
2006; 4: 53
Decreased wheel-running activity in hamsters post myocardial infarction
2006; 4: 51
Pancreatic islet cell therapy for type I diabetes: understanding the effects of glucose stimulation on islets in order to produce better islets for transplantation
2007; 5: 1
Clinical relevance of Neutral Endopeptidase (NEP/CD10) in melanoma
2007; 5: 2
Up-regulation of HLA class-I antigen expression and antigen-specific CTL response in cervical cancer cells by the demethylating agent hydralazine and the histone deacetylase inhibitor valproic acid
2006; 4: 55
Therapeutic use of Aldara™ in chronic myeloid leukemia
2007; 5: 4
Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells
2007; 5: 5
Immune-mediated changes in actinic keratosis following topical treatment with imiquimod 5% cream
2007; 5: 7
The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization
2007; 5: 6
Cord blood in regenerative medicine: do we need immune suppression?
2007; 5: 8
Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma
2007; 5: 3
CD8 apoptosis may be a predictor of T cell number normalization after immune reconstitution in HIV
2007; 5: 9
Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models
2007; 5: 10
Gene expression profiling of cutaneous wound healing
2007; 5: 11
Calcium Sulfate and Platelet-Rich Plasma make a novel osteoinductive biomaterial for bone regeneration
2007; 5: 13